A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT Study)

American Journal of Transplantation

Volumn 10, Issue 3, 2010, Pages 535-546

  Vincenti, F ^a   Charpentier, B ^b   Vanrenterghem, Y ^c   Rostaing, L ^d   Bresnahan, B ^e   Darji, P ^f   Massari, P ^g   Mondragon Ramirez, G A ^h   Agarwal, M ⁱ   Di Russo, G ⁱ   Lin, C S ⁱ   Garg, P ⁱ   Larsen, C P ^j  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BICÊTRE HOSPITAL   (France)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f Sterling Hospital   (India)

^g HOSPITAL PRIVADO   (Argentina)

^h Instituto Mexicano de Transplantes   (Mexico)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j EMORY UNIVERSITY   (United States)

more..

Author keywords

Belatacept; Cyclosporine; Kidney; Renal function

Indexed keywords

BASILIXIMAB; BELATACEPT; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; ABATACEPT; ANTIBODY CONJUGATE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ADULT; ANEMIA; ARTICLE; BONE CANCER; BREAST CANCER; BRONCHITIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FEVER; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROENTERITIS; GLOMERULUS FILTRATION RATE; GRAFT DYSFUNCTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; INJECTION SITE REACTION; KIDNEY CARCINOMA; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY STRUCTURE; LEUKEMIA; LUNG TUMOR; LYMPHOCELE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SARCOMA; SEPSIS; SIDE EFFECT; THRUSH; THYROID TUMOR; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VIRUS INFECTION; INCIDENCE; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MIDDLE AGED; PROCEDURES; RISK FACTOR; TIME;

ADULT; CYCLOSPORINE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; RISK FACTORS; TIME FACTORS;

EID: 76949101581     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.03005.x     Document Type: Article

References (52)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004 4 : 378 383.
2. United Network for Organ Sharing National Data. Available at : http://www.unos.org/. 2008. Accessed November 15, 2009.
3. United States Renal Data System. USRDS 2008 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. http://www.usrds.org/adr.htm. Bethesda, MD : National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2008.
4. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003 349 : 2326 2333.
5. Ducloux D, Motte G, Kribs M et al. Hypertension in renal transplantation: Donor and recipient risk factors. Clin Nephrol 2002 57 : 409 413.
6. Roland M, Gatault P, Doute C et al. Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation. Transpl Int 2008 21 : 523 530.
7. Vincenti F, Friman S, Scheuermann E et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007 7 : 1506 1514.
8. Mathis AS, Dave N, Knipp GT, Friedman GS. Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm 2004 61 : 565 585.
9. Berber I, Aydin C, Yigit B et al. Blood pressure and graft outcome in renal transplantation. Transplant Proc 2005 37 : 997 998.
10. Porrini E, Delgado P, Bigo C et al. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis 2006 48 : 134 142.
11. Matas AJ, Gillingham KJ, Humar A et al. Posttransplant diabetes mellitus and acute rejection: Impact on kidney transplant outcome. Transplantation 2008 85 : 338 343.
12. Ortiz F, Paavonen T, Tornroth T et al. Predictors of renal allograft histologic damage progression. J Am Soc Nephrol 2005 16 : 817 824.
13. Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G. Ischemic heart disease-major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995 60 : 451 457.
14. Vanrenterghem YF, Claes K, Montagnino G et al. Risk factors for cardiovascular events after successful renal transplantation. Transplantation 2008 85 : 209 216.
15. Larsen CP, Pearson TC, Adams AB et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005 5 : 443 453.
16. Vincenti F, Larsen C, Durrbach A et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005 353 : 770 781.
17. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999 55 : 713 723. (Pubitemid 29082898)
18. Wilson DM, Bergert JH, Larson TS, Liedtke RR. GFR determined by nonradiolabeled iothalamate using capillary electrophoresis. Am J Kidney Dis 1997 30 : 646 652.
19. Pei R, Wang G, Tarsitani C et al. Simultaneous HLA Class I and Class II antibodies screening with flow cytometry. Hum Immunol 1998 59 : 313 322.
20. Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003 75 : 43 49.
21. Vaidya S, Cooper TY, Avandsalehi J et al. Improved flow cytometric detection of HLA alloantibodies using pronase: Potential implications in renal transplantation. Transplantation 2001 71 : 422 428.
22. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999 130 : 461 470.
23. Levey AS, Coresh J, Greene T et al. Expressing the MDRD study equation for estimating GFR with IDMS traceable (gold standard) serum creatinine values. J Am Soc Nephrol 2005 16 : 69A.
24. Koch DD, Gansky SA. Statistical considerations for multiplicity in confirmatory protocols. Drug Inf J 1996 30 : 523 534.
25. Medical and Statistical Review and Evaluation (tacrolimus). Silver Spring, MD, US : Food and Drug Administration/Center for Drug Evaluation and Research. 1997.
26. Medical and Statistical Review and Evaluation (mycophenolate sodium delayed-release tablets). Silver Spring, MD, US : Food and Drug Administration/Center for Drug Evaluation and Research. 2004.
27. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997 63 : 39 47.
28. Sollinger H, Kaplan B, Pescovitz MD et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 2001 72 : 1915 1919.
29. Stuart F. Overview of living and deceased organ donors, immunosuppression, and outcomes. In : Stuart F, Abecassis M, Kaufman D, eds. Organ Tranplantation. Georgetown : Landes Bioscience, 2000 : 52 53.
30. Vincenti F, Ramos E, Brattstrom C et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001 71 : 1282 1287.
31. Fellstrom B, Jardine AG, Soveri I et al. Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: Experience from the Assessment of Lescol in Renal Transplantation trial. Transplantation 2005 79 : 1160 1163. (Pubitemid 40664016)
32. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002 62 : 311 318.
33. Kasiske BL, Andany MA, Danielson B. A thirty percent chronic decline in inverse serum creatinine is an excellent predictor of late renal allograft failure. Am J Kidney Dis 2002 39 : 762 768.
34. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003 75 : 1291 1295.
35. Ekberg H, Tedesco-Silva H, Demirbas A et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007 357 : 2562 2575.
36. Buchler M, Caillard S, Barbier S et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007 7 : 2522 2531.
37. Gill JS, Tonelli M, Mix CH, Pereira BJ. The change in allograft function among long-term kidney transplant recipients. J Am Soc Nephrol 2003 14 : 1636 1642.
38. Rao PS, Schaubel DE, Jia X, Li S, Port FK, Saran R. Survival on dialysis post-kidney transplant failure: Results from the Scientific Registry of Transplant Recipients. Am J Kidney Dis 2007 49 : 294 300.
39. Asberg A, Midtvedt K, Line PD et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation 2006 82 : 62 68.
40. Hernandez D, Miquel R, Porrini E et al. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. Transplantation 2007 84 : 706 714.
41. Kliem V, Fritsche L, Haller H et al. Cyclosporine-based immunosuppressive strategies for kidney recipients: Interim analysis of German data from the Multinational Observational Study (MOST). Transplant Proc 2005 37 : 1597 1600.
42. Silva HT Jr., Yang HC, Abouljoud M et al. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007 7 : 595 608.
43. Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008 8 : 307 316.
44. Latek R, Fleener C, Lamian V et al. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation 2009 87 : 926 933.
45. Fellstrom B, Holdaas H, Jardine AG et al. Risk factors for reaching renal endpoints in the Assessment of Lescol in Renal Transplantation trial. Transplantation 2005 79 : 205 212.
46. He X, Johnston A. Early acute rejection does not affect chronic allograft nephropathy and death censored graft failure. Transplant Proc 2004 36 : 2993 2996.
47. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004 4 : 1289 1295.
48. Bluestone JA, Liu W, Yabu JM et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008 8 : 2086 2096.
49. Bestard O, Cruzado JM, Rama I et al. Presence of FoxP3+ regulatory T Cells predicts outcome of subclinical rejection of renal allografts. J Am Soc Nephrol 2008 19 : 2020 2026.
50. Muthukumar T, Dadhania D, Ding R et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005 353 : 2342 2351.
51. Li XC, Rothstein DM, Sayegh MH. Costimulatory pathways in transplantation: Challenges and new developments. Immunol Rev 2009 229 : 271 293.
52. Abrams JR, Lebwohl MG, Guzzo CA et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999 103 : 1243 1252.